Ice-Controlled Cryopreservation Redefines Cell Therapy Standards: CellStore Bio Showcases Breakthrough Solutions at CSGCT 2025

As cell therapy enters a market valued in the hundreds of billions, “post-cryopreservation decline in cell quality” remains the industry’s most significant pain point—characterized by reduced viability, functional deterioration, and inter-batch inconsistency. How can we safeguard this primordial energy of life?

On September 12–13, at the 2nd China Society for Gene and Cell Therapy (CSGCT) Conference, CellStore will make a prominent appearance with its globally leading controlled-rate freezing and cryopreservation technology. Addressing the challenges of cryopreservation through four core guarantees—“fidelity, viability, functionality, and safety”—the company will unveil two revolutionary products: immune cell cryopreservation medium and stem cell cryopreservation medium.

The Pain of Traditional CryopreservationRapid ice crystal growth punctures cell membranes, osmotic pressure changes cause cellular dehydration and shrinkage, and strong hydrogen bonding leads to protein denaturation and inactivation... These industry-wide challenges, which result in cell death or loss of viability during cryopreservation, stem from the fact that traditional vitrification requires the addition of cryoprotectants yet fails to completely inhibit ice crystal formation.

CellStore's Approach to CryopreservationDisruptive "Controlled-Rate Freezing and Cryopreservation Technology," developed over more than a decade, breaks through three major technical barriers:

• Controlled Ice Cryopreservation Technology: Regulating ice crystal growth through biomimetic ice control mechanisms to avoidCell Cryopreservationdamage, achieving a serum-free, protein-free, and animal component-free cryopreservation solution.

• Pharmacopoeia-Grade Formula: All ingredients meet pharmaceutical standards, with clearly defined components and high safety profiles; registered as pharmaceutical excipients with the National Medical Products Administration (NMPA).

• Operational Revolution: Ready-to-use design eliminates the need for programmed cooling, allowing direct storage at -80°C, significantly simplifying workflows and reducing equipment dependency.

✅ Fidelity: Ensures that the sample composition remains unchanged and gene expression does not undergo significant changes

✅ Viability Preservation: Ensures sample viability with a viable cell recovery rate >95%

✅ Preserves Functionality: Ensures the functional integrity of samples, maintaining consistent viability before and after cryopreservation.

✅ Ensures Safety: Fully pharmacopoeia-grade formula, with all ingredients meeting pharmaceutical standards, clearly defined composition, and high safety profile.

Golden Armor for Immune Cells—CS-AT-D2 Cryopreservation Solution

• Viability Preservation: Addresses issues such as reduced viability and receptor shedding in CAR-T/NK cells after cryopreservation, and is also suitable for the cryopreservation of various other immune cell types

• Potent Cytotoxicity: Breaking Through Technical Barriers, Post-Revival Cell Cytotoxicity Exceeds 95%

Stem Cell Vitality Capsule — CS-SC-D1 Cryopreservation Solution

• Viability Guarantee: Cell viability remains unchanged after cryopreservation and recovery, with a viable cell recovery rate of >90%.

• Maintenance of Stemness: MSCs Retain Robust Adhesion, Proliferation, and Differentiation Capacities Post-Cryopreservation

Scan QR Code to Register

From preserving the spark of life to safeguarding the industrial upgrading of cell-based therapies, CellStore is leveraging its “controlled-rate freezing and cryopreservation technology” as a fulcrum to drive the upgrade of cryopreservation standards in the field of cell therapy. This September, at the Exhibition and Trading Center of Zhongguancun National Independent Innovation Demonstration Zone, we cordially invite you to witness the revolutionary breakthroughs in cryopreservation technology and join hands in charting a new blueprint for the cell therapy industry!

To Promote ChinaCGTDriven by technological breakthroughs, industrial integration, policy alignment, and international cooperation in the field, China’s CGT industry is advancing to the forefront of global competition, giving rise to the China Society for Gene and Cell Therapy (CSGCT) Conference.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, and applications in the global cell and gene therapy field, provide insights on market access, highlight high-quality collaboration opportunities, and facilitate matchmaking between overseas investors and investment seekers. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global value chain.

The conference closely addressed the industry's hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, covering the latest advancements in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, tumor vaccines, as well as clinical applications and breakthroughs, CMC and testing, AI-driven drug R&D, registration and regulation, and investment, financing, and BD matchmaking.Comprehensive coverage across the entire industry chain.

2025 2nd China Cell and Gene Therapy (CSGCT) Congress

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, please scan the QR code to visit the official conference website.